Search

CN-122011177-A - Monoclonal antibody pair for helicobacter pylori adhesion A and application thereof

CN122011177ACN 122011177 ACN122011177 ACN 122011177ACN-122011177-A

Abstract

The invention belongs to the technical field of immunology, and particularly relates to a monoclonal antibody pair aiming at helicobacter pylori adhesion A and application thereof. The invention discloses an anti-HpaA monoclonal antibody pair which is named as an MM07 antibody and an MM14 antibody respectively, and discloses a corresponding coding gene, a test strip containing the monoclonal antibody pair and a kit. The results of the examples show that the monoclonal antibodies of the invention have good specificity and sensitivity for HpaA antigen.

Inventors

  • XU GUANGXIAN
  • YANG WEIQIANG
  • ZENG YIWEI
  • JIANG DAN
  • YU LUXIN
  • CUI KAI
  • CHEN RUI

Assignees

  • 东莞市东南部中心医院(东莞市东南部中医医疗服务中心、广东医科大学附属东莞第一医院)

Dates

Publication Date
20260512
Application Date
20260228

Claims (10)

  1. 1. A monoclonal antibody pair against helicobacter pylori adhesin a, characterized in that the antibody pair is an MM07 antibody and an MM14 antibody; The heavy chain variable region of the MM07 antibody comprises heavy chain CDR1-3, and the amino acid sequence of the heavy chain CDR1-3 is shown as SEQ ID NO 4-6; The light chain variable region of the MM07 antibody comprises light chain CDR1-3, and the amino acid sequence of the light chain CDR1-3 is shown as SEQ ID NO 9-11; The heavy chain variable region of the MM14 antibody comprises heavy chain CDR1-3, and the amino acid sequence of the heavy chain CDR1-3 is shown as SEQ ID NO. 14-16; The light chain variable region of the MM14 antibody comprises light chain CDR1-3, and the amino acid sequence of the light chain CDR1-3 is shown as SEQ ID NO. 19-21.
  2. 2. The antibody pair of claim 1, wherein the heavy chain variable region of the MM07 antibody comprises an amino acid sequence as set forth in SEQ ID No. 3, or an amino acid sequence that is at least 75% identical to the sequence set forth in SEQ ID No. 3 and has binding capacity for HpaA; The light chain variable region of the MM07 antibody comprises an amino acid sequence as set forth in SEQ ID No. 8, or an amino acid sequence having at least 75% identity to the sequence set forth in SEQ ID No. 8 and having the ability to bind HpaA; The heavy chain variable region of the MM14 antibody comprises an amino acid sequence as shown in SEQ ID NO. 13, or an amino acid sequence which has at least 75% identity to the sequence shown in SEQ ID NO. 13 and has the ability to bind to HpaA; the light chain variable region of the MM14 antibody comprises an amino acid sequence as shown in SEQ ID NO. 18, or an amino acid sequence which has at least 75% identity to the sequence shown in SEQ ID NO. 18 and has the ability to bind to HpaA.
  3. 3. A nucleic acid molecule encoding the monoclonal antibody pair of claim 1 or 2.
  4. 4. The nucleic acid molecule of claim 3, wherein the sequence encoding the heavy chain variable region of the MM07 antibody comprises the nucleotide sequence set forth in SEQ ID No. 2; The nucleic acid molecule codes for the light chain variable region of the MM07 antibody and comprises a nucleotide sequence shown as SEQ ID NO. 7; the sequence of the nucleic acid molecule encoding the heavy chain variable region of the MM14 antibody comprises a nucleotide sequence shown as SEQ ID NO. 12; The sequence of the nucleic acid molecule encoding the light chain variable region of the MM14 antibody comprises a nucleotide sequence shown as SEQ ID NO. 17.
  5. 5. A biological material, characterized in that the biological material is a biological material expressing the monoclonal antibody pair of claim 1 or 2, and the biological material comprises a carrier or a cell.
  6. 6. Use of a monoclonal antibody pair according to claim 1 or 2 or a monoclonal antibody pair produced by encoding a nucleic acid molecule according to claim 3 or 4 or a monoclonal antibody pair expressed by a biological material according to claim 5 for the detection of HpaA or for the preparation of a product for the detection of HpaA.
  7. 7. The use according to claim 6, wherein the use is in the detection of helicobacter pylori or in the preparation of a product for the detection of helicobacter pylori.
  8. 8. A test strip or kit comprising a monoclonal antibody pair according to claim 1 or 2 or a monoclonal antibody pair produced by encoding a nucleic acid molecule according to claim 3 or 4 or a monoclonal antibody pair expressed by a biological material according to claim 5.
  9. 9. The test strip or kit according to claim 8, wherein the MM14 antibody is used as a coating antibody and the MM07 antibody is used as a labeling antibody.
  10. 10. Use of a test strip or kit according to claim 8 or 9 for the detection of helicobacter pylori.

Description

Monoclonal antibody pair for helicobacter pylori adhesion A and application thereof Technical Field The invention belongs to the technical field of immunology, and particularly relates to a monoclonal antibody pair aiming at helicobacter pylori adhesion A and application thereof. Background Helicobacter pylori adhesin A (Helicobacter pylori adhesin A, hpaA) is mainly located on the surface of the helicobacter pylori outer membrane, and plays a key role in mediating the adhesion of bacteria to host gastric epithelial cells, and is one of the important factors of helicobacter pylori pathogenicity. HpaA is a lipoprotein with a transmembrane signal peptide sequence which can be anchored on the surface of the outer membrane, and its expression is closely related to adhesion, colonization and chronic infection of helicobacter pylori. During infection, the immunostimulatory effect of HpaA is closely linked to the formation of chronic inflammatory responses, and HpaA-mediated host cell adhesion is critical for H.pylori colonization of the gastric mucosa. HpaA has strong immunogenicity, can induce a host to produce specific antibodies, and can detect high-titer anti-HpaA antibodies in serum of helicobacter pylori infected people. The immunological detection method of helicobacter pylori includes serum ELISA detection, fast diagnosis test paper, etc. and has the advantages of simple operation, low cost and non-invasive performance, and is suitable for large scale epidemiological investigation and preliminary screening. Immunological detection is based on antigen-antibody reaction, and therefore, is based on highly conserved, highly specific antigens, which are key to immunological diagnosis of helicobacter pylori infection. Helicobacter pylori adhesin a (HpaA), cytotoxin-related gene a protein (CagA), vacuolate toxin a (VacA), urease (Urease) and the like are the most studied and used antigens currently, however, high-performance detection antibodies against these key antigens are still relatively limited. In order to meet the increasing demand of accurate detection, the development of more novel and efficient helicobacter pylori specific antibodies is of great significance. Disclosure of Invention The invention aims to provide a monoclonal antibody pair aiming at helicobacter pylori adhesion A and application thereof, and the antibody provided by the invention has good specificity and sensitivity to HpaA. In order to achieve the above object, the present invention provides the following technical solutions: the invention provides a monoclonal antibody pair aiming at helicobacter pylori adhesion A, wherein the antibody pair is an MM07 antibody and an MM14 antibody; The heavy chain variable region of the MM07 antibody comprises heavy chain CDR1-3, and the amino acid sequence of the heavy chain CDR1-3 is shown as SEQ ID NO 4-6; The light chain variable region of the MM07 antibody comprises light chain CDR1-3, and the amino acid sequence of the light chain CDR1-3 is shown as SEQ ID NO 9-11; The heavy chain variable region of the MM14 antibody comprises heavy chain CDR1-3, and the amino acid sequence of the heavy chain CDR1-3 is shown as SEQ ID NO. 14-16; The light chain variable region of the MM14 antibody comprises light chain CDR1-3, and the amino acid sequence of the light chain CDR1-3 is shown as SEQ ID NO. 19-21. Preferably, the method comprises the steps of, The heavy chain variable region of the MM07 antibody comprises an amino acid sequence as set forth in SEQ ID No. 3, or an amino acid sequence having at least 75% identity to the sequence set forth in SEQ ID No. 3 and having the ability to bind HpaA; The light chain variable region of the MM07 antibody comprises an amino acid sequence as set forth in SEQ ID No. 8, or an amino acid sequence having at least 75% identity to the sequence set forth in SEQ ID No. 8 and having the ability to bind HpaA; The heavy chain variable region of the MM14 antibody comprises an amino acid sequence as shown in SEQ ID NO. 13, or an amino acid sequence which has at least 75% identity to the sequence shown in SEQ ID NO. 13 and has the ability to bind to HpaA; the light chain variable region of the MM14 antibody comprises an amino acid sequence as shown in SEQ ID NO. 18, or an amino acid sequence which has at least 75% identity to the sequence shown in SEQ ID NO. 18 and has the ability to bind to HpaA. The invention also provides a nucleic acid molecule which codes for the monoclonal antibody pair according to the technical scheme. Preferably, the method comprises the steps of, The sequence of the nucleic acid molecule encoding the heavy chain variable region of the MM07 antibody comprises a nucleotide sequence shown as SEQ ID NO. 2; The nucleic acid molecule codes for the light chain variable region of the MM07 antibody and comprises a nucleotide sequence shown as SEQ ID NO. 7; the sequence of the nucleic acid molecule encoding the heavy chain variable region of the MM14 antibody co